Fcγ-receptor-activation by circulating immune complexes in systemic autoimmune diseases and its reduction by CD19-CAR T cell therapy.

Objectives The role of autoantibody-producing B cells in connective tissue diseases (CTD) has recently been highlighted by the successful treatment with CD19-targeting CAR T cells. Detrimental effects of autoantibodies are linked to the formation of deposited IgG complexes and the activation of immu...

Full description

Bibliographic Details
Published in:Rheumatology Vol. 65; no. 3; pp. 1 - 11
Main Authors: Freitag, Merle, Kolb, Philipp, Falcone, Valeria, Claus, Maren, Schröder, Pauline, Andreeva, Ivana, Rodon, Lea, Ewald, Meike, Deicher, Franca Sophie, Stütz, Ayla Nadja
Format: pictorial research tables/charts Journal Article
Published: Oxford University Press / USA Mar2026
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=192667737&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 192667737
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        14620324
        DN9
      jtl: Rheumatology
      issn: 14620324
      maglogo: N
    pubinfo:
      dt: Mar2026
      vid: 65
      iid: 3
      pid: 622
      pub: Oxford University Press / USA
    artinfo:
      ui:
        192667737
        192667737
        192667737
        10.1093/rheumatology/keaf627
        192667737
      ppf: 1
      ppct: 10
      formats:
      tig:
        atl: Fcγ-receptor-activation by circulating immune complexes in systemic autoimmune diseases and its reduction by CD19-CAR T cell therapy.
      aug:
        au:
          Freitag, Merle
          Kolb, Philipp
          Falcone, Valeria
          Claus, Maren
          Schröder, Pauline
          Andreeva, Ivana
          Rodon, Lea
          Ewald, Meike
          Deicher, Franca Sophie
          Stütz, Ayla Nadja
        affil: Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
      sug:
        subj:
          Autoimmune Diseases Immunology
          Immunotherapy
          Receptors, Immunologic
          Connective Tissue Diseases Immunology
          Human
          Funding Source
          Female
          Male
          Adolescence
          Adult
          Middle Age
          Aged
          Aged, 80 and Over
          Cross Sectional Studies
          Prospective Studies
          Descriptive Statistics
          Data Analysis Software
          Mann-Whitney U Test
          Kruskal-Wallis Test
          Chi Square Test
          Spearman's Rank Correlation Coefficient
          Multiple Linear Regression
          Flow Cytometry
          Sjogren's Syndrome
          Lung Diseases, Interstitial
          Autoantibodies Immunology
          Adolescent: 13-18 years
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Aged, 80 & over
          Female
          Male
      ab: Objectives The role of autoantibody-producing B cells in connective tissue diseases (CTD) has recently been highlighted by the successful treatment with CD19-targeting CAR T cells. Detrimental effects of autoantibodies are linked to the formation of deposited IgG complexes and the activation of immune cells via Fcγ receptors (FcγRs). The role of circulating immune complexes (cICs) as a link between adaptive and innate immunity has remained understudied. Clinical testing of cICs has been hindered by the lack of reliable detection methods. The aim of this study was to determine the potential of IgG-containing cICs to activate FcγRs (their bioactivity) using a new detection method. Methods A reporter cell platform was used to assess the presence and bioactivity of cICs in IgG-autoantibody-positive CTD patients (cross-section analysis) and in patients treated with CD19-CAR T cells (longitudinal analysis). Results The bioactivity of cICs in the cohort of patients with CTDs was significantly higher compared with healthy controls and patients with IgG-autoantibody-negative systemic inflammatory disease (psoriatic arthritis). Analyses of individual diseases revealed the presence of cICs in the sera of all CTDs, including systemic sclerosis (SSc) and primary Sjögren's syndrome, although there was significant heterogeneity among individuals. Within SSc, patients positive for anti-topoisomerase-I (Scl70) autoantibodies, diffuse cutaneous and lung involvement had significantly enhanced cIC bioactivity. Finally, the bioactivity of cICs was significantly reduced in CTD patients after CD19-CAR T cell therapy. Conclusions Our study reveals the presence of FcγR-engaging cICs in CTDs and demonstrates that the bioactivity of cICs is correlated with clinical phenotypes and treatment outcomes.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N